Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
about
Retargeting Strategies for Oncolytic Herpes Simplex VirusesNucleic acid targeting: towards personalized therapy for head and neck cancer.Effect of ultrasound on herpes simplex virus infection in cell culture.A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulationPresage of oncolytic virotherapy for oral cancer with herpes simplex virus.Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.Targeting cancer-initiating cells with oncolytic viruses.A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.The Herpes Simplex Virus Neurovirulence Factor γ34.5: Revealing Virus-Host Interactions.Future directions and treatment strategies for head and neck squamous cell carcinomasA novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma.Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human seraTrial watch: Oncolytic viruses for cancer therapyPotent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft modelsRegional liver therapy using oncolytic virus to target hepatic colorectal metastases.Use of attenuated paramyxoviruses for cancer therapy.Rethinking herpes simplex virus: the way to oncolytic agents.Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progressAdvance in herpes simplex viruses for cancer therapy.Viral gene therapy for head and neck cancer.Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.The current status of oncolytic viral therapy for head and neck cancer.Stability and anti-tumor effect of oncolytic herpes simplex virus type 2.
P2860
Q26765439-C0085F9D-3461-47D9-BE9B-B0B969E3BEF7Q26850237-8833A11C-55AD-44AD-B38F-51B7729585E1Q30473768-1C289B41-E334-467A-8D0D-AA7A011DEFCDQ33554262-7569744C-5421-4AE2-BE9A-886C5056E48FQ33566511-BF4CE9C5-C11C-468A-9DC0-181106016393Q33603748-F92A24D0-24B0-4ACB-932D-35A7096C3F0EQ34275711-00FA74B7-E65C-4451-A6DF-C087DDD0EC8BQ34659011-8BF49B66-556F-4301-A62A-AABD7777E3EEQ34808441-15CAC51D-CAA8-4753-A90F-C3515CFB9197Q35060701-4FBCDE87-6A35-4749-9212-956AF36FF789Q35699072-3444AEFC-9628-430B-BD16-EFA91A1B818AQ35823934-3DE2E3EB-9365-4F5F-896B-4AAB53032FCDQ35952866-5F77E8D3-D4C1-428E-8FB2-A4D1CA0B8814Q36177257-00497F5C-48A8-476D-B89C-E183135AE013Q36299683-DCB0B4E2-379E-451F-8182-3B54666D94E3Q36664273-4BD45604-C002-4774-95B1-407398DACEE5Q36700993-AFD64B96-1729-4325-9133-6776685A4A03Q37028023-47701A55-BAB7-4E69-8212-70F830743A36Q37031733-BD777660-B9B7-445C-8A53-52EF9F513E9CQ37759934-93F532CD-2EE3-4D7A-B57A-1AAD8354EEA9Q37810599-1B6B2CA2-F837-48E3-8FCB-8C0C0A35FE06Q37882608-C6EFC640-852F-4B6A-B149-1990744758D5Q37899230-F2BF38ED-C5A6-4BB9-B547-8048807E8936Q38096940-551BF3FD-CAA2-4B3F-A619-ADF355702A8EQ38381706-BAAF1400-E185-4554-AC94-8BA005E66130Q39427382-F871D1DC-A834-4AA6-B5CD-91B9035674F2Q39925879-0C350F7F-AAA1-4312-94E9-649E76542F1CQ52859083-2821FFA5-2BB2-4814-830D-DAD192D72E70Q54974000-5BFE9D45-4A9A-4AED-B941-B37F35342F21
P2860
Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Potential for efficacy of the ...... oral squamous cell carcinoma.
@ast
Potential for efficacy of the ...... oral squamous cell carcinoma.
@en
Potential for efficacy of the ...... oral squamous cell carcinoma.
@nl
type
label
Potential for efficacy of the ...... oral squamous cell carcinoma.
@ast
Potential for efficacy of the ...... oral squamous cell carcinoma.
@en
Potential for efficacy of the ...... oral squamous cell carcinoma.
@nl
prefLabel
Potential for efficacy of the ...... oral squamous cell carcinoma.
@ast
Potential for efficacy of the ...... oral squamous cell carcinoma.
@en
Potential for efficacy of the ...... oral squamous cell carcinoma.
@nl
P2093
P356
P1433
P1476
Potential for efficacy of the ...... oral squamous cell carcinoma.
@en
P2093
Alastair T M Mace
David S Soutar
S Moira Brown
P304
P356
10.1002/HED.20840
P50
P577
2008-08-01T00:00:00Z